September 14, 2015

Encouraging early results of a major 10,000 patient NHS lung cancer screening trial using EarlyCDT®-Lung have been announced, attracting attention across UK national news.  ITN news  and The Times highlighted new positive results from the National Health Service (NHS) Scotland ECLS study.

The study is the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted. The initial results were presented in full by Professor Frank Sullivan, Chief Investigator of the ECLS study, at the IASLC’s 16th World Conference on Lung Cancer, on 7th September. In summary, the trial showed the cancer pick up rate to be considerably better than the stated test performance.

Geoffrey Hamilton-Fairly, CEO of Oncimmune, said: “If these results continue, it will further underpin the rationale of the ECLS study – namely that screening with EarlyCDT-Lung can be effective for the early detection of lung cancer, helping save lives and money for healthcare providers.”

EarlyCDT-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer.


Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept